<?xml version="1.0" encoding="UTF-8"?>
<p>Although cytomegalovirus remains an important viral infection posttransplant, other viruses such as HSV I and 2 and VZV are significant pathogens. Ganciclovir and valganciclovir are used for posttransplant viral prophylaxis [
 <xref ref-type="bibr" rid="CR184">184</xref>]. CMV-negative transplant recipients who receive an organ from a CMV seropositive donor are at increased risk to develop CMV reactivation posttransplant. CMV seropositive recipients have a lower risk and CMV donor/recipient negative patients the least risk of CMV activation [
 <xref ref-type="bibr" rid="CR185">185</xref>, 
 <xref ref-type="bibr" rid="CR186">186</xref>]. Infection with the CMV virus increases risk for bacterial and fungal infections and leads to an almost fourfold increased risk of death by a year posttransplant [
 <xref ref-type="bibr" rid="CR187">187</xref>â€“
 <xref ref-type="bibr" rid="CR191">191</xref>].
</p>
